1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Perinatal Infections Market Outlook
4.1.
Market Size &
Forecast
4.1.1. By Value
4.2.
Market Share &
Forecast
4.2.1.
By Infection Type (Cytomegalovirus Infection, Enterovirus
Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus,
Listeriosis Lymphocytic Choriomeningitis Virus, Rubella, Syphilis, Varicella,
Others)
4.2.2.
By Treatment (Antibiotics, Antiviral, Antiretroviral,
Others)
4.2.3.
By Diagnosis (Maternal Test, Neonatal Test, Others)
4.2.4.
By End user (Hospitals & Clinics,
Ambulatory Care Centers, Others)
4.2.5. By
Region
4.2.6. By Company (2023)
4.3.
Market Map
4.3.1. By Infection Type
4.3.2. By Treatment
4.3.3. By Diagnosis
4.3.4. By End user
4.3.5. By Region
5. Asia Pacific Perinatal Infections Market
Outlook
5.1.
Market Size &
Forecast
5.1.1. By Value
5.2.
Market Share &
Forecast
5.2.1. By
Infection Type
5.2.2. By
Treatment
5.2.3.
By Diagnosis
5.2.4. By End
user
5.2.5. By Country
5.3.
Asia Pacific:
Country Analysis
5.3.1. China Perinatal Infections Market Outlook
5.3.1.1.
Market Size & Forecast
5.3.1.1.1.
By Value
5.3.1.2.
Market Share & Forecast
5.3.1.2.1.
By Infection Type
5.3.1.2.2.
By Treatment
5.3.1.2.3.
By Diagnosis
5.3.1.2.4.
By End user
5.3.2. India Perinatal Infections Market Outlook
5.3.2.1.
Market Size & Forecast
5.3.2.1.1.
By Value
5.3.2.2.
Market Share & Forecast
5.3.2.2.1.
By Infection Type
5.3.2.2.2.
By Treatment
5.3.2.2.3.
By Diagnosis
5.3.2.2.4.
By End user
5.3.3. Australia Perinatal Infections Market Outlook
5.3.3.1.
Market Size & Forecast
5.3.3.1.1.
By Value
5.3.3.2.
Market Share & Forecast
5.3.3.2.1.
By Infection Type
5.3.3.2.2.
By Treatment
5.3.3.2.3.
By Diagnosis
5.3.3.2.4.
By End user
5.3.4. Japan Perinatal Infections Market Outlook
5.3.4.1.
Market Size & Forecast
5.3.4.1.1.
By Value
5.3.4.2.
Market Share & Forecast
5.3.4.2.1.
By Infection Type
5.3.4.2.2.
By Treatment
5.3.4.2.3.
By Diagnosis
5.3.4.2.4.
By End user
5.3.5. South Korea Perinatal Infections Market
Outlook
5.3.5.1.
Market Size & Forecast
5.3.5.1.1.
By Value
5.3.5.2.
Market Share & Forecast
5.3.5.2.1.
By Infection Type
5.3.5.2.2.
By Treatment
5.3.5.2.3.
By Diagnosis
5.3.5.2.4.
By End user
6. Europe Perinatal Infections Market Outlook
6.1.
Market Size &
Forecast
6.1.1. By Value
6.2.
Market Share &
Forecast
6.2.1. By
Infection Type
6.2.2. By
Treatment
6.2.3.
By Diagnosis
6.2.4. By End
user
6.2.5. By
Country
6.3.
Europe: Country
Analysis
6.3.1. France Perinatal Infections Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Infection Type
6.3.1.2.2.
By Treatment
6.3.1.2.3.
By Diagnosis
6.3.1.2.4.
By End user
6.3.2. Germany Perinatal Infections Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Infection Type
6.3.2.2.2.
By Treatment
6.3.2.2.3.
By Diagnosis
6.3.2.2.4.
By End user
6.3.3. Spain Perinatal Infections Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Infection Type
6.3.3.2.2.
By Treatment
6.3.3.2.3.
By Diagnosis
6.3.3.2.4.
By End user
6.3.4. Italy Perinatal Infections Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Infection Type
6.3.4.2.2.
By Treatment
6.3.4.2.3.
By Diagnosis
6.3.4.2.4.
By End user
6.3.5. United Kingdom Perinatal Infections Market
Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Infection Type
6.3.5.2.2.
By Treatment
6.3.5.2.3.
By Diagnosis
6.3.5.2.4.
By End user
7. North America Perinatal Infections Market
Outlook
7.1.
Market Size &
Forecast
7.1.1. By Value
7.2.
Market Share &
Forecast
7.2.1. By
Infection Type
7.2.2. By
Treatment
7.2.3.
By Diagnosis
7.2.4. By End
user
7.2.5. By Country
7.3.
North America:
Country Analysis
7.3.1. United States Perinatal Infections Market
Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Infection Type
7.3.1.2.2.
By Treatment
7.3.1.2.3.
By Diagnosis
7.3.1.2.4.
By End user
7.3.2. Mexico Perinatal Infections Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Infection Type
7.3.2.2.2.
By Treatment
7.3.2.2.3.
By Diagnosis
7.3.2.2.4.
By End user
7.3.3. Canada Perinatal Infections Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Infection Type
7.3.3.2.2.
By Treatment
7.3.3.2.3.
By Diagnosis
7.3.3.2.4.
By End user
8. South America Perinatal Infections Market
Outlook
8.1.
Market Size &
Forecast
8.1.1. By Value
8.2.
Market Share &
Forecast
8.2.1. By
Infection Type
8.2.2. By
Treatment
8.2.3.
By Diagnosis
8.2.4. By End
user
8.2.5. By Country
8.3.
South America:
Country Analysis
8.3.1. Brazil Perinatal Infections Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Infection Type
8.3.1.2.2.
By Treatment
8.3.1.2.3.
By Diagnosis
8.3.1.2.4.
By End user
8.3.2. Argentina Perinatal Infections Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Infection Type
8.3.2.2.2.
By Treatment
8.3.2.2.3.
By Diagnosis
8.3.2.2.4.
By End user
8.3.3. Colombia Perinatal Infections Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Infection Type
8.3.3.2.2.
By Treatment
8.3.3.2.3.
By Diagnosis
8.3.3.2.4.
By End user
9. Middle East and Africa Perinatal Infections
Market Outlook
9.1.
Market Size &
Forecast
9.1.1. By Value
9.2.
Market Share &
Forecast
9.2.1. By
Infection Type
9.2.2. By
Treatment
9.2.3.
By Diagnosis
9.2.4. By End
user
9.2.5. By Country
9.3.
MEA: Country
Analysis
9.3.1. South Africa Perinatal Infections Market
Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Infection Type
9.3.1.2.2.
By Treatment
9.3.1.2.3.
By Diagnosis
9.3.1.2.4.
By End user
9.3.2. Saudi Arabia Perinatal Infections Market
Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Infection Type
9.3.2.2.2.
By Treatment
9.3.2.2.3.
By Diagnosis
9.3.2.2.4.
By End user
9.3.3. UAE Perinatal Infections Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Infection Type
9.3.3.2.2.
By Treatment
9.3.3.2.3.
By Diagnosis
9.3.3.2.4.
By End user
10.
Market Dynamics
10.1.
Drivers
10.2.
Challenges
11.
Market Trends &
Developments
11.1.
Recent Developments
11.2.
Product Launches
11.3.
Mergers &
Acquisitions
12.
Global Perinatal
Infections Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1.
Competition in the
Industry
13.2.
Potential of New
Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute
Product
14.
Competitive
Landscape
14.1. Merck KGaA
14.1.1.
Business Overview
14.1.2.
Company Snapshot
14.1.3.
Product &
Services
14.1.5.
Financials (In case
of listed)
14.1.6.
Recent Developments
14.1.7.
SWOT Analysis
14.2. Beckman Coulter Inc.
14.3. Bio-Rad Laboratories, Inc
14.4. Hologic Inc.
14.5. Gilead Sciences, Inc.
14.6. Emcure Pharmaceuticals Limited.
14.7. Cipla Inc.
14.8. Bausch Health Companies Inc
14.9. Johnson & Johnson
14.10.Teva Pharmaceutical Industries
Ltd.
15.
Strategic Recommendations
16. About Us & Disclaimer